BRCA susceptibility genes - A Review of current conservative management of BRCA mutation carriers

Three options for the management of a patient carrying a deleterious mutation in the BRCA gene exist: close surveillance, chemoprevention and prophylactic surgical procedures. We aimed at reviewing the current knowledge on the conservative management of patients who are found to be carriers of the BRCA susceptibility genes. Recent literature in the English language was reviewed for publications containing the conservative management of BRCA mutation-carriers. Close surveillance for the breasts includes breast self-examination, clinical examination by a specialist and breast imaging techniques--mammography and magnetic resonance imaging. Ovarian surveillance includes pelvic examination, transvaginal ultrasonography and blood CA-125 measurements. Age at beginning of examinations and their frequency are discussed. Chemoprevention includes tamoxifen and oral contraceptives for breast and ovarian cancer prevention, respectively.

BRCA mutation; Breast cancer; Ovarian cancer; Chemoprevention; Mammography

[1] Lynch H., Krush A.: "Carcinoma of the breast and ovary in three families". Surg. Gynecol. Obstet., 1971, 133, 644.

[2] Miki Y.,Swensen J., Shattuck-Edens D. et al.: "A strong candidate for the breast and ovarian cancer susceptiblity gene BRCA 1 " Science, 1994, 266, 66.

[3] Wooster R., Bignell G., Lancaster J. et al.: "Identification of the breast cancer susceptibility gene BRCA2". Nature, 1995, 378, 789

[4] Thomas D., Gao D., Ray R. et al.: "Randomized trial of breast self-examination in Shanghai: final results". J. Natl. Cancer Inst., 2002, 94, 1445.

[5] Goffin J., Chappuis P.O., Wong N., Foulkes W.D.: "Magnetic resonance imaging and mammography in women with a high hereditary risk of breast cancer". J. Natl. Cancer Inst., 2001, 93, 1754 [letter].

[6] Stoutjesdijk M.J., Boetes C., Jager G.J. et al.: "Magnetic Resonance Imaging and Mammography in women with a hereditary risk of breast cancer". J. Natl. Cancer Inst., 2001, 93, 1095.

[7] Kuhl C.K., Schmutzler R.K., Leutner C.C. et al.: "Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results". Radiology, 2000, 215, 267.

[8] Sharan S.K., Morimatsu M., Albrecht U. et al.: "Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2". Nature, 1997, 386, 804.

[9] Menon U., Jacobs I.: "Screening for ovarian cancer". Best Practice & Research Clinic Obstet. Gynecol., 2002, 16, 469.

[10] NIH Consensus Panel on Ovarian Cancer: "Ovarian cancer. Screening, treatment and follow-up". J. Amer. Med. Assoc., 1995, 273, 491.

[11] Burke W., Daly M., Garber J. et al.: "Recommendations for follow-up care of individuals with an inherited predisposition to cancer II. BRCAl and BRCA2. Cancer Genetics Studies Consortium". J. Amer. Med. Assoc., 1997, 277, 997.

[12] Narod S.A., Brunet J-S., Ghadirian P., Robson M., Heimdal K., Neuhausen S.L. et al.: "Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study". Lancet, 2000, 356, 1876.

[13] Lakhani S.R., van de Vijver M.J., Jacquemier J. et al.: "T he pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2 and p53 in patients with mutations in BRCA 1 and BRCA2". J. Clin. Oncol., 2002, 20, 2310.

[14] Rebbeck T.R., Lynch H.T., Neuhausen S.L. et al.: "Prophylactic oophorectomy in carriers of BRCA 1 or BRCA2 mutations". N. Engl. J. Med., 2002, 346, 1616.

[15] Johannsson 0., Loman N., Borg A., Olsson H.: "Pregnancy-associated breast cancer in BRCA 1 and BRCA2 germline mutation carriers". Lancet, 1998, 352, 1359.

[16] Jernstrom H., Lerman C., Ghadirian P., et al.:. "Pregnancy and risk of early breast cancer in carriers of BRCA 1 and BRCA2". Lancet, 1999, 354, 1846-50.

[17] Powles T., Eel es R., Ashley S. et al.: "Interim analysis of the incident breast cancer in the Royal Marsden Hospital tamoxifen randomized prevention trial". Lancet, 1998, 362, 98.

[18] King M.C., Wieand S., Hale K. et al.: "Tamoxifen and breast cancer incidence among women with inherited mutations in BRCAI and BRCA2: National Surgical Adjuvant Breast and Bowel Project NSABP-Pl) Breast Cancer Prevention Trial". J. Amer. Med. Assoc., 2001, 286, 2251.

[19] Duffi S.W., Nixon R.M.: "Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA 1 and BRCA2 mutations". Brit. J. Cancer, 2002, 86, 218.

[20] Narod S.A., Risch H., Moslehi R. et al.: "Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group". N. Engl. J. Med., 1998, 339, 424.

[21] Marchbank、P.A., McDonald J.A., Wilson H.G. et al.: "Oral contraceptives and the risk of breast cancer". N. Engl. J. Med., 2002, 346, 2025.

[22] Grabrick D.M., Hartmann L.C., Cerhan J.R. et al.: "Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer". J. Amer. Med. Assoc., 2000, 284, 1791.

[23] Modan B., Hartge P., Hirsh-Yechezkel G. et al.: "Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA l Or BRCA2 mutation". N. Engl. J. Med., 2001, 345, 235.

[24] Narod S.A., Dube M-P., Klijn J. et al.: "Oral contraceptives and the risk of breast cancer in BRCA I and BRCA2 mutation carriers".J. Natl. Cancer Inst., 2002, 94, 1773.

[25] Eisen A., Rebbeck T.R., Wood W.C., Weber B.L.: "Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer". J. Clin. Oneal., 2000, 18, 1980.